Skip to main content
Kinarus Therapeutics Holding AG logo

Kinarus Therapeutics Holding AG — Investor Relations & Filings

Ticker · KNRS ISIN · CH1330780979 LEI · 506700VDL70GGMHR5758 SW Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2024-04-26 M&A Activity
Country CH Switzerland
Listing SW KNRS

About Kinarus Therapeutics Holding AG

https://www.curatis.com/

Formerly Kinarus Therapeutics Holding AG, the company now operates as Curatis Holding AG, a specialty pharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines for rare and specialty care diseases. The company's operations are divided into two segments. The distribution business acquires, licenses, and distributes third-party medicines for orphan and specialty diseases. The development business advances a pipeline of novel drug candidates, prioritizing compounds with existing safety and efficacy data to accelerate development. Key development programs target conditions such as peritumoral brain edema, severe migraine with aura, and medication overuse headache.

Recent filings

Filing Released Lang Actions
Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed
M&A Activity Classification · 99% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and details the completion of a 'Business Combination' between Kinarus Therapeutics Holding AG and Curatis AG, including corporate restructuring (reverse share split, capital increase) and financing details (Mandatory Exchangeable Loan Note). This type of announcement, detailing a significant corporate action like a merger/acquisition and related financing/restructuring, fits best under Capital/Financing Update (CAP) or M&A Activity (TAR). Since the core event is the completion of the business combination (merger/acquisition) and the document focuses heavily on the resulting entity and its pipeline, TAR (M&A Activity) is a strong candidate. However, the document also details significant capital structure changes (reverse split, share issuance, loan note conversion) and fundraising (CHF 4.36m raised). Given the explicit mention of 'Acquisition/Corporate Action' as a keyword and the focus on the combination itself, TAR is slightly more specific than CAP, although CAP is also relevant due to the financing aspects. Since the document is a formal, non-standard regulatory announcement (Ad hoc announcement) detailing a major corporate transaction (merger/acquisition), TAR is the most appropriate classification for the transaction itself.
2024-04-26 English
Insider Regulations
Governance Information Classification · 95% confidence The document is a formal internal policy titled 'Regulations on Insider Trading Prevention and Securities Trading' for Curatis Holding AG. It outlines legal compliance, definitions of insider information, trading prohibitions, and internal procedures for employees and directors. This type of document falls under corporate governance and internal regulatory compliance policies, which are best categorized as 'Governance Information' (CGR) within the provided schema.
2024-04-25 English
Organizational Regulations
Governance Information Classification · 95% confidence The document is titled 'Organizational Regulations of Curatis Holding AG' and outlines the internal governance structure, board responsibilities, committee charters, and management delegation. It is a foundational corporate governance document that defines how the company is run, rather than a financial report, an announcement, or a specific regulatory filing like a 10-K or proxy statement. Among the provided categories, 'Governance Information' (CGR) is the most accurate classification for internal organizational regulations and governance policies.
2024-04-25 English
Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split
Report Publication Announcement Classification · 100% confidence The document is an 'Ad hoc announcement pursuant to Art. 53 LR' from Kinarus Therapeutics Holding AG. It explicitly states the 'Publication of audited Consolidated & Statutory FY2023 Financial Statements' and provides key figures from these statements. However, it also announces the 'postponement of the publication of the Annual Report 2023' and provides a future date for the full Annual Report (May 24, 2024). Since the document publishes the audited financial statements for the year (FY2023) but is *not* the full Annual Report (10-K), it most closely aligns with the comprehensive financial reporting for a period shorter than a year, or in this case, the primary annual financial results release, which is often categorized as an Interim/Quarterly Report (IR) when the full 10-K is delayed, or sometimes as an Earnings Release (ER) if it were quarterly. Given the context of publishing *audited FY2023 Financial Statements* and the explicit mention of the Annual Report being postponed, this functions as the primary release of annual financial performance data. Since '10-K' is reserved for the official yearly report, and this document explicitly publishes the audited financial statements while announcing the delay of the full Annual Report, 'IR' (Interim/Quarterly Report, often used for comprehensive period reports) is the closest fit among the options for a detailed financial disclosure that isn't the final 10-K. Alternatively, because it is an ad-hoc announcement detailing the release of audited annual figures, it could be seen as an Earnings Release (ER) if we interpret 'ER' broadly for major results announcements, but 'IR' better captures the comprehensive nature of the published statements. Given the focus on FY2023 audited statements, and the explicit mention of the Annual Report being delayed, I will classify it as the release of the core financial data, which is often captured by 'IR' when the 10-K is pending. However, since this is the *Annual* result, and the document is an ad-hoc announcement about the results and related corporate actions (M&A, share split), it is a major regulatory disclosure. If the document were only announcing the results without providing the statements themselves, ER would be better. Since it *publishes* the audited statements, it is more than just an ER. Given the options, and the fact that it is an announcement about the *release* of the audited annual figures, it is a strong candidate for an Earnings Release (ER) or a Regulatory Filing (RNS). Since it contains the actual financial statements (albeit summarized), ER is a strong fit for the release of annual results. I will select ER as it announces the results, even though the full 10-K is pending.
2024-04-17 English
Annual financial report 2023
Audit Report / Information Classification · 100% confidence The document is a formal 'Report of the statutory auditor' for Kinarus Therapeutics Holding AG, which includes the balance sheet, income statement, and detailed notes to the financial statements for the fiscal year ending December 31, 2023. It is prepared by Ernst & Young Ltd and contains the auditor's opinion, emphasis of matter regarding going concern, and financial tables. This constitutes a standalone audit report and financial statement package, which falls under the Audit Report / Information category. FY 2023
2024-04-17 English
Annual financial report 2023
Audit Report / Information Classification · 98% confidence The document is a formal 'Report of the statutory auditor' for Kinarus Therapeutics Holding AG, which includes the consolidated financial statements (balance sheet, income statement, cash flows, and notes) for the fiscal year ended 31 December 2023. While it contains an audit report, the inclusion of the full consolidated financial statements and notes indicates this is the primary annual financial reporting document, which falls under the 10-K category for annual reports. FY 2023
2024-04-17 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.